GLP-1 pill race heats up as Wegovy tablet holds strong against Lilly rival [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
Novo Nordisk's (NYSE:NVO) Wegovy pill, the oral version of its blockbuster GLP-1 (glucagon-like peptide-1) weight-loss treatment, is tracking at roughly twice the prescription volumes of Eli Lilly's competing oral drug at the same stage of launch, according to Citi. The Danish drugmaker's tablet reached around 124,000 total prescriptions in its 15th week on the US market, in the week ending 17 April, representing 10% week-on-week growth, based on IQVIA prescription data. That compares favourably with Zepbound, Lilly's injectable obesity treatment, at the equivalent point in its own launch, though Citi notes the IQVIA data does not fully capture direct-to-patient cash-pay channels, which may understate the true Wegovy pill volume. The figures also represent the first meaningful read-across since Lilly launched Foundayo, its oral GLP-1 drug orforglipron, in the US on 9 April. IQVIA recorded around 3,700 Foundayo prescriptions in the week ending 17 April, its first full week of
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Boehringer-Zealand drug leads to 16.6% weight loss in late-stage trial [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk Rare Disease Wins Add Context To Undervalued Share Price [Yahoo! Finance]Yahoo! Finance
- Is This Deal a Game Changer for Novo Nordisk? [Yahoo! Finance]Yahoo! Finance
- Is This Deal a Game Changer for Novo Nordisk? [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 4/27/26 - Form 6-K
- 4/20/26 - Form 6-K
- 4/20/26 - Form 6-K
- NVO's page on the SEC website